AstraZeneca vaccine and rare thrombosis risk, an alternative to the product developed by the University of Oxford will be offered in the UK for people under 40, where available. The decision follows the recommendations of the Joint Committee on Vaccination and Immunization on the risks of thrombosis, specifying that this must not slow down the vaccination campaign. Read also People between the ages of 30 and 39 will therefore be offered the possibility of vaccinating themselves with Pfizer / BioNTech or Nih / Moderna in Great Britain.
